Edwards Lifesciences Corp

More Details of Edwards Lifesciences Corp Company

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Company Info

Company codeEW

Company nameEdwards Lifesciences Corp

IPO dateMar 27, 2000

Founded at1999

CEOMr. Bernard J. Zovighian

Number of employees15800

Security typeOrdinary Share

Fiscal year-endMar 27

AddressOne Edwards Way

CityIRVINE

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code92614

Phone19492502500

Websitehttps://www.edwards.com

Company codeEW

IPO dateMar 27, 2000

Founded at1999

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

273.31K

--

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

178.00K

-0.19%

Mr. Steven R. (Steve) Loranger

Independent Director

71.32K

--

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

22.23K

--

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

17.95K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

13.29K

-51.80%

Mr. Paul A. Laviolette

Independent Director

7.72K

-3.16%

Dr. David T. Feinberg, M.D.

Independent Director

2.31K

--

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

273.31K

--

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

178.00K

-0.19%

Mr. Steven R. (Steve) Loranger

Independent Director

71.32K

--

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

22.23K

--

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

17.95K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

13.29K

-51.80%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

By RegionUSD

Name

Revenue

Proportion

United States

3.21B

58.94%

Europe

1.32B

24.30%

Rest of the world

572.00M

10.52%

Japan

339.80M

6.25%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

Shareholder

Update time: Wed, Apr 16

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.71%

Wellington Management Company, LLP

5.65%

BlackRock Institutional Trust Company, N.A.

5.40%

State Street Global Advisors (US)

4.39%

Geode Capital Management, L.L.C.

2.32%

Other

70.53%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.71%

Wellington Management Company, LLP

5.65%

BlackRock Institutional Trust Company, N.A.

5.40%

State Street Global Advisors (US)

4.39%

Geode Capital Management, L.L.C.

2.32%

Other

70.53%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

44.56%

Investment Advisor

31.06%

Hedge Fund

3.82%

Pension Fund

2.37%

Research Firm

2.13%

Bank and Trust

1.79%

Sovereign Wealth Fund

1.50%

Individual Investor

0.89%

Endowment Fund

0.82%

Other

11.06%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2552

530.96M

90.30%

-2.24M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

2022Q4

2485

532.76M

86.16%

-12.94M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

68.87M

11.71%

+6.55M

+10.50%

Dec 31, 2024

Wellington Management Company, LLP

33.21M

5.65%

+1.68M

+5.32%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

31.74M

5.4%

-1.09M

-3.33%

Dec 31, 2024

State Street Global Advisors (US)

25.81M

4.39%

-457.01K

-1.74%

Dec 31, 2024

Geode Capital Management, L.L.C.

13.65M

2.32%

+126.19K

+0.93%

Dec 31, 2024

JP Morgan Asset Management

10.76M

1.83%

+6.05M

+128.20%

Dec 31, 2024

Fisher Investments

9.78M

1.66%

+696.97K

+7.68%

Dec 31, 2024

Citadel Advisors LLC

9.42M

1.6%

+7.43M

+372.91%

Dec 31, 2024

Walter Scott & Partners Ltd.

9.41M

1.6%

-720.79K

-7.12%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

8.25M

1.4%

-285.79K

-3.35%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

iShares U.S. Medical Devices ETF

4.32%

Future Fund Long/Short ETF

3.05%

Global X Aging Population ETF

2.15%

Themes US R&D Champions ETF

1.97%

Tema Cardiovascular and Metabolic ETF

1.77%

iShares Health Innovation Active ETF

1.67%

SPDR S&P Health Care Equipment ETF

1.61%

ROBO Global Healthcare Technology & Innovation ETF

1.56%

Invesco S&P 500 Equal Weight Health Care ETF

1.54%

First Trust Indxx Medical Devices ETF

1.41%

iShares U.S. Medical Devices ETF

Proportion4.32%

Future Fund Long/Short ETF

Proportion3.05%

Global X Aging Population ETF

Proportion2.15%

Themes US R&D Champions ETF

Proportion1.97%

Tema Cardiovascular and Metabolic ETF

Proportion1.77%

iShares Health Innovation Active ETF

Proportion1.67%

SPDR S&P Health Care Equipment ETF

Proportion1.61%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.56%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.54%

First Trust Indxx Medical Devices ETF

Proportion1.41%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

May 07, 2020

Split

1>3

Date

Type

Ratio

May 07, 2020

Split

1>3

76.280USD

Edwards Lifesciences Corp

76.280

Overview

Company